FDA Adverse Event Malfunction Summary report: N

LUMIRADX SARS-COV-2 AG TEST STRIP KIT

MDR report key: 14630966 · Received June 8, 2022

Report

Report Number
3012642695-2022-00213
Event Type
Malfunction
Date Received
June 8, 2022
Date of Event
May 25, 2022
Report Date
June 8, 2022
Manufacturer
LUMIRADX UK LTD.
Product Code
QKP
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
WA, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 0

PATIENT REPORTED AS SYMPTOMATIC WITH AN ACTIVE COUGH. INITIAL LUMIRADX SARS-COV-2 AG TEST WAS PERFORMED ON (B)(6) 2022 WITH STRIP LOT 7000040. THE INITIAL TEST RESULT WAS POSITIVE. CONFIRMATORY TESTING WAS PERFORMED VIA POLYMERASE CHAIN REACTION (PCR). THE CONFIRMATORY TEST RESULT WAS NEGATIVE. ALL CUSTOMER REPORTED PRODUCT HANDLING PRACTICES ARE CONSISTENT WITH PRODUCT INSERT AND SWABS USED HAVE BEEN VALIDATED FOR USE WITH THE LUMIRADX SARS-COV-2 AG TEST. NO PATIENT HARM, INJURY OR ADVERSE HEALTH CONSEQUENCES WERE COMMUNICATED BY THE CUSTOMER TO LUMIRADX FOR THE REPORTED DISCORDANT RESULT. HOWEVER, THE CUSTOMER IDENTIFIED THE PATIENT'S SCHEDULED MEDICAL PROCEDURE WAS CANCELLED, DESPITE A NEGATIVE PCR RESULT, WITHIN APPROXIMATELY ONE HOUR OF INITIAL TEST. REVIEW OF PRODUCT RISK ASSESSMENT CONFIRMED THE APPLICABLE RISK CATEGORIES REMAIN APPROPRIATE FOR THE REPORTED EVENT. REVIEW OF MANUFACTURING RECORDS IDENTIFIED THAT THE REPORTED STRIP LOT MET ALL DEFINED QC CRITERIA AT THE TIME IT WAS RELEASED, AND THAT IN-HOUSE TESTING CONFIRMED STRIP LOT MET EXPECTED PERFORMANCE CRITERIA FOR USE IN THE FIELD. REVIEW OF TRENDING DATA FOR DISCORDANT RESULTS WAS REVIEWED AND THE OCCURRENCE RATE FOR THE REPORTED STRIP LOT CONTINUES TO DEMONSTRATE FIELD PERFORMANCE WITHIN SPECIFICATION OF PRODUCT CLAIMS, RELATIVE TO THE QUANTITY OF STRIPS IN THE FIELD. ROOT CAUSE DETERMINATION: NO DEFINITIVE ROOT CAUSE HAS BEEN DETERMINED FOR THE REPORTED DISCORDANT RESULT BASED ON THE INFORMATION CURRENTLY AVAILABLE. INVESTIGATION CONCLUSION AND STATUS OF INVESTIGATION: NO FURTHER INVESTIGATION IS CONSIDERED NECESSARY AT THIS TIME. THIS STRIP LOT CONTINUES TO DEMONSTRATE FIELD PERFORMANCE WITHIN SPECIFICATION OF PRODUCT CLAIMS, RELATIVE TO THE QUANTITY OF STRIPS IN THE FIELD. REPORTS OF DISCORDANT RESULTS FOR THIS LOT WILL CONTINUE TO BE TRENDED AND REVIEWED, WITH ACTION TAKEN AS APPROPRIATE IN RESPONSE TO ANY ADVERSE TRENDS OR EVENTS INCLUDING A FOLLOW-UP REPORT.

Description of Event or Problem · 0

THIS IS REPORT 4 OF 4 FOR THIS FACILITY AND AWARE DATE. THE CUSTOMER REPORTED A SUSPECTED FALSE (INCORRECT) POSITIVE RESULT FROM A RAPID RESULT COVID TEST SYSTEM ON AN INDIVIDUAL PATIENT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2290050 LUMIRADX SARS-COV-2 AG TEST STRIP KIT CORONAVIRUS ANTIGEN DETECTION TEST SYSTEM, QKP LUMIRADX UK LTD. 7000040

Patients

Seq Age Sex Outcome Treatment
1 9 MO Unknown LUMIRADX SMART DIAGNOSTIC PLATFORM| STERIPACK NASAL SWABS